“The higher prices of medicines in the United States, condemned by President Trump, are the result of a fully privatised system that contributes to increasing all items of health expenditure. On the contrary, our National Health Service, also thanks to AIFA’s work, is able to obtain among the most favourable prices for medicines among OECD countries”, said AIFA’s President Robert Nisticò.

“However, we cannot ignore the fact that pharmaceutical spending in Italy is also constantly increasing. It is therefore necessary to take action on governance, identifying tools that allow to reward only genuine innovation, one that can demonstrate with real data a concrete therapeutic benefit for citizens”.